基立福 GRFS 深 滬
等待開盤 09-08 09:30:00 美东时间
7.80
-0.080
-1.02%
華盛通- 最 高7.84
- 今 開7.82
- 成交量 15.79万股
- 最 低 7.77
- 昨 收 7.88
- 總市值 53.09亿
- 52周最高 10.1443
- 市盈率 靜 11.70
- 換手率 0.02%
- 52周最低 6.8743
- 委 比 -86.94%
- 總股本 6.81亿
- 歷史最高 24.9989
- 量 比 0.39
- 振 幅 0.89%
- 歷史最低 -0.0079
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Grifols Biologicals LLC旗下10批次人血白蛋白获广东药检院予以签发
8月31日消息，国家药品监督管理局旗下广东省药品检验所披露的生物制品批签发产品公示情况显示，2026年8月24日至2026年8月30日，广东省药品检验所共批签发...
08-31 20:16
Grifols Biologicals旗下3批次人血白蛋白获广东药检院予以签发
8月17日消息，国家药品监督管理局旗下广东省药品检验所披露的生物制品批签发产品公示情况显示，2026年8月10日至2026年8月16日，广东省药品检验所共批签发...
08-17 20:17
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols has completed the clinical portion of its SPARTA phase 3 trial, evaluating the efficacy and safety of Prolastin-C in treating emphysema caused by alpha-1 antitrypsin deficiency. The trial, the largest of its kind, involved 345 participants across 16 countries and used CT densitometry to measure lung tissue loss. Topline results are expected by late 2026. Grifols remains committed to advancing innovation in alpha-1 treatment through resear...
08-10 11:00
Grifols旗下6批次人血白蛋白获广东药检院予以签发
8月7日消息，国家药品监督管理局旗下广东省药品检验所披露的生物制品批签发产品公示情况显示，2026年7月27日至2026年8月2日，广东省药品检验所共批签发4...
08-07 20:16
Grifols S.A. Q2 2026 Earnings Preview
Grifols S.A. (GRFS) is scheduled to announce Q2 earnings results on Tuesday, July 28th, before market open. The consensus EPS Estimate is $0.28 and the consensus Revenue Estimate is $2.15B Over the la...
07-28 02:12
Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin
Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C,...
07-16 20:02
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has initiated two Phase 3 trials to expand U.S. labels for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The SIGMA trial evaluates GAMUNEX-C in preventing infections in patients with secondary immunodeficiency, particularly those with blood cancers. The XPERT trial compares XEMBIFY's efficacy and safety to GAMUNEX-C in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Both studies aim to provide more treatm...
07-16 12:00
